Aromatase inhibitors (AIs) block estrogen synthesis and profoundly suppress serum estrogen levels. When used to treat ER positive breast cancer, it is therefore counterproductive to prescribe systemic estrogen alongside an AI. The gene discussed is ESR1; the disease is breast cancer.